Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02795858
Title A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field